Lead Product(s) : Pegmolesatide
Therapeutic Area : Nephrology
Study Phase : Phase IV
Recipient : The First Affiliated Hospital of Dalian Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 27, 2025
Lead Product(s) : Pegmolesatide
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Recipient : The First Affiliated Hospital of Dalian Medical University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HS-10390
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 10, 2024
Lead Product(s) : HS-10390
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HS-10390
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 12, 2023
Lead Product(s) : HS-10390
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegol-Sihematide
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein-drug Conjugate
Upfront Cash : Inapplicable
April 04, 2019
Lead Product(s) : Pegol-Sihematide
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegol-Sihematide
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With NDD-CKD
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein-drug Conjugate
Upfront Cash : Inapplicable
April 04, 2019
Lead Product(s) : Pegol-Sihematide
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegol-Sihematide
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein-drug Conjugate
Upfront Cash : Inapplicable
October 26, 2015
Lead Product(s) : Pegol-Sihematide
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EPO-018B
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 31, 2015
Lead Product(s) : EPO-018B
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EPO-018B
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 19, 2015
Lead Product(s) : EPO-018B
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable